Company intelligence / Profile preview
PhorMed
Nevada, United Statesphormed.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed Phase 1 establishing safety validity of their drug. Currently in Phase 2 for 3 clinical studies. Helped 83% of AML patients beat cancer, delivers significant tumor reduction in Hodgkin's Lymphoma, reduces lung inflammation in ARDS, and reduces brain inflammation in Parkinson's disease. FDA has Fast-Tracked Phase 1 and Phase 2 for both cancer studies.
- Therapeutic areas
- OncologyPulmonologyNeurology
- Modalities
- Cell repair therapyGene Repair Therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on PhorMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhorMed.